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Liver toxicity following preparatory regimen
(prep-reg) for bone marrow transplantation
(BMT) creates one of the major problems in
the early post-BMT period, especially in
patients (pts.) with pretransplant HCV and/or
HBV infections, and liver dysfunction. This
gave rise to the search for prep-reg, that
would be less hepatotoxic, but would still
have sufficient antileukemic effect. Therefore,
we compared liver function in children
prepared for allo-BMT with busulfan-
containing and with hyperfractionated TBI-
containing regimens.
Patients and methods: Seventeen pts. have
been conditioned with busulfan-containing
prep-reg (10 with BuVpCy, 7 with BuCy) (Bu-
group). Diagnosis consisted of ALL (6) and
AML (11). All pts. from Bu-group have been
transplanted with bone marrow from HLA-
identical, MLC· non-reactive siblings.
Pretransplant screening showed positive
HBsAg in one patient, and HCV antibody in 6
pts. For GvHD prevention CsA+MTX have
been given in 12 pts., CsA+MTX+PRED in 3
pts., and CsA alone in 2 pts. Acute GvHD 11-
IVo occured in 4 pts. Hyperfractionated TBI
(hFTBI) (2 x 1,5 Gy on 4 consecutive days)
was employed in 10 pts. (hFTBI+Cy in 6 pts.,
hFTBI+Vp in 4 pts.) (hFTBI-group). Nine pts.
were transplanted for ALL, and one child for
AML. Nine pts. from hFTBI-group have been
transplanted with bone marrow from HLA-
identical, MLC non-reactive siblings, and one
child from a syngeneic twin. For GvHD
prevention 5 pts. have been treated with
CsA+MTX, 2 with CsA+PRED, and 2 with CsA
alone (recipient of syngeneic bone marrow
received no GvHD prophylaxis). Acute GvHD
11 0 was observed in one child. For HVOD
prevention in all children from both groups
continuous infusion of alprostadil and/or low-
dose heparin (100 units/kg/day) has been
administered. Total bilirubine concentration,
alanine aminotransferase (AIAt) and aspartate
aminotransferase (AspAt) activity were
measured in serum on day -10, -1, +7, +14,
+21, +28 and +35 by automated chemical
analysis using standard reagents.
Results: One child (AML, pos. HCV antibody,
BuCy, CsA alone for GvHD prevention) from
Bu-group developed on day +18 day recurrent
form of severe HVOD leading to the death on
day +102. Conclusions: According to liver
function parameters observed till day +35 post-
BMT, i.e. during the period, when the risk of
HVOD is highest, hFTBI seems to be less
hepatotoxic than busulfan-containing prep-reg.
Therefore BM-recipients with liver dysfunction
observed prior to BMT should rather be
prepared for transplantation with hFTBI.
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